| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
In MCF10A and MDA-MB-468 cells, ANI-7 (2.5 μM; 24 h) treatment significantly arrested the S-phase and G2 + M-phase cell cycle with minimal effects. in MCF10A cells from normal breasts [1]. DNA double-strand damage was indicated by a large increase in H2AXɣ and a considerable rise in CHK2 level and phosphorylation in MDA-MB-468 cells after treatment with ANI-7 (2 μM) for 12-24 hours [1]. Enhancing the effects of ANI-7 is AhR pathway inhibition. AhR and CYP1 member expression, as well as XRE activity, are activated by ANI-7 [1]. A comparison of GI50 values revealed that MCF-7 cells produced a GI50 value of 0.38 μM in response to ANI-7, while lung, colon, ovarian, neuronal, glial, prostate, and pancreatic cell lines showed values of 3.0. -42 micrometers. The A431 vulvar cell line (GI50 of 0.51 μM) is the only other tumor type that exhibits notable growth inhibition by ANI-7 [1][1]. ANI-7 essentially failed to inhibit the growth of MDA-MB-231 and MCF10A cells (GI50 range 17-26μM), but it moderately inhibits the growth of BT20 and BT474 cells (GI50 range 1-2μM), and effectively inhibits the growth of T47D, ZR-75-1, MCF-7, SKBR3, and MDA-MB-468 breast cancer cells (GI50 range 0.16-0.38μM). Furthermore, drug-resistant cells (MCF-7/VP16: GI50 of 0.21 μM) can still not be grown by ANI-7 [1].
|
|---|---|
| Cell Assay |
Cell cycle analysis[1]
Cell Types: MCF10A and MDA-MB-468 Cell Tested Concentrations: 2.5 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induction of significant S phase and G2 + M phase cell cycle arrest in MDA-MB-468 cells , the effect on normal breast MCF10A cells is negligible. Western Blot Analysis [1] Cell Types: MDA-MB-468 Cell Tested Concentrations: 2 μM Incubation Duration: 12 hrs (hours), 24 hrs (hours) Experimental Results: resulted in a significant increase in the content and phosphorylation of CHK2 (25-fold increase), and induced H2AXɣ Dramatically increased (by 3.5 times). |
| References |
|
| Molecular Formula |
C13H8CL2N2
|
|---|---|
| Molecular Weight |
263.122020721436
|
| Exact Mass |
262.006
|
| CAS # |
931417-26-4
|
| PubChem CID |
11565176
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
345
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(/C1C=CC(Cl)=C(Cl)C=1)(\C#N)=C\C1NC=CC=1
|
| InChi Key |
IJJHHDLGGYDXGD-UXBLZVDNSA-N
|
| InChi Code |
InChI=1S/C13H8Cl2N2/c14-12-4-3-9(7-13(12)15)10(8-16)6-11-2-1-5-17-11/h1-7,17H/b10-6+
|
| Chemical Name |
(Z)-2-(3,4-dichlorophenyl)-3-(1H-pyrrol-2-yl)prop-2-enenitrile
|
| Synonyms |
ANI7; ANI 7
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20.83 mg/mL (~79.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8005 mL | 19.0027 mL | 38.0055 mL | |
| 5 mM | 0.7601 mL | 3.8005 mL | 7.6011 mL | |
| 10 mM | 0.3801 mL | 1.9003 mL | 3.8005 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
